These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31975037)
1. Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Croci GA; Hoster E; Beà S; Clot G; Enjuanes A; Scott DW; Cabeçadas J; Veloza L; Campo E; Clasen-Linde E; Goswami RS; Helgeland L; Pileri S; Rymkiewicz G; Reinke S; Dreyling M; Klapper W Virchows Arch; 2020 Aug; 477(2):259-267. PubMed ID: 31975037 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma. Jing C; Zheng Y; Feng Y; Cao X; Xu C Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776 [TBL] [Abstract][Full Text] [Related]
3. SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. Xu J; Wang L; Li J; Saksena A; Wang SA; Shen J; Hu Z; Lin P; Tang G; Yin CC; Wang M; Medeiros LJ; Li S Am J Surg Pathol; 2019 May; 43(5):710-716. PubMed ID: 30768440 [TBL] [Abstract][Full Text] [Related]
4. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350 [TBL] [Abstract][Full Text] [Related]
5. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679 [TBL] [Abstract][Full Text] [Related]
8. [Expression of SOX11 mRNA in mantle cell lymphoma and its clinical significance]. Wang YY; Yu Z; Yi SH; Li ZJ; Li CH; Xie ZQ; Li F; Zang MR; Hao M; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):556-60. PubMed ID: 22967417 [TBL] [Abstract][Full Text] [Related]
9. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11. Wu B; Li J; Wang H; Wu Q; Liu H Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593 [TBL] [Abstract][Full Text] [Related]
10. Association of SOX11 gene expression withclinical features and prognosis of mantle cell lymphoma. He JX; Xi YF; Su LP; Gao N; Xu EW; Xie LW; Wang LY; Zheng YP; Han WE; Chang J; Wang HW Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2556-2563. PubMed ID: 29771407 [TBL] [Abstract][Full Text] [Related]
11. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. Beà S; Amador V Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437 [TBL] [Abstract][Full Text] [Related]
12. Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Ruan J; Martin P Curr Hematol Malig Rep; 2016 Jun; 11(3):234-40. PubMed ID: 27068437 [TBL] [Abstract][Full Text] [Related]
13. SOX11, a key oncogenic factor in mantle cell lymphoma. Beekman R; Amador V; Campo E Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333 [TBL] [Abstract][Full Text] [Related]
14. Elevated SOX11 mRNA level correlates with favorable prognosis in mantle cell lymphoma. He J; Xi Y; Gao N; Xu E; Xie L; Chang J; Liu J J BUON; 2019; 24(4):1679-1685. PubMed ID: 31646825 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma. Wang X; Björklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B PLoS One; 2010 Nov; 5(11):e14085. PubMed ID: 21124928 [TBL] [Abstract][Full Text] [Related]
16. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307 [TBL] [Abstract][Full Text] [Related]
17. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples. Zhang YH; Liu J; Dawlett M; Guo M; Sun X; Gong Y Cancer Cytopathol; 2014 Dec; 122(12):892-7. PubMed ID: 25056830 [TBL] [Abstract][Full Text] [Related]
18. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064 [TBL] [Abstract][Full Text] [Related]